SK1732003A3 - Substituted imidazoles as TAFIa inhibitors - Google Patents

Info

Publication number

SK1732003A3

SK1732003A3 SK173-2003A SK1732003A SK1732003A3 SK 1732003 A3 SK1732003 A3 SK 1732003A3 SK 1732003 A SK1732003 A SK 1732003A SK 1732003 A3 SK1732003 A3 SK 1732003A3

Authority

SK

Slovakia

Prior art keywords

formula

group

compound

hydrogen

compounds

Prior art date

2000-08-17

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003112 inhibitor Substances 0.000 title claims abstract description 97
• 150000002460 imidazoles Chemical class 0.000 title description 5
• 150000001875 compounds Chemical class 0.000 claims abstract description 384
• 230000003176 fibrotic effect Effects 0.000 claims abstract description 22
• 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 16
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
• 101800004538 Bradykinin Proteins 0.000 claims abstract description 14
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims abstract description 14
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims abstract description 14
• 208000027866 inflammatory disease Diseases 0.000 claims abstract description 11
• 230000037390 scarring Effects 0.000 claims abstract description 5
• 201000011510 cancer Diseases 0.000 claims abstract description 4
• 102100035792 Kininogen-1 Human genes 0.000 claims abstract 6
• 238000002360 preparation method Methods 0.000 claims description 233
• 239000000203 mixture Substances 0.000 claims description 122
• 238000000034 method Methods 0.000 claims description 95
• 229910052739 hydrogen Inorganic materials 0.000 claims description 65
• 239000001257 hydrogen Substances 0.000 claims description 61
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 58
• 125000000217 alkyl group Chemical group 0.000 claims description 53
• 238000011282 treatment Methods 0.000 claims description 44
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 40
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 39
• -1 aromatic heterocycle Chemical group 0.000 claims description 37
• 150000003839 salts Chemical class 0.000 claims description 37
• 125000003118 aryl group Chemical group 0.000 claims description 33
• 239000003814 drug Substances 0.000 claims description 31
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 29
• 208000007536 Thrombosis Diseases 0.000 claims description 28
• 229910052736 halogen Inorganic materials 0.000 claims description 26
• 150000002367 halogens Chemical class 0.000 claims description 26
• 229940002612 prodrug Drugs 0.000 claims description 26
• 239000000651 prodrug Substances 0.000 claims description 26
• 125000002947 alkylene group Chemical group 0.000 claims description 23
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 22
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 22
• 239000012453 solvate Substances 0.000 claims description 22
• 102000009123 Fibrin Human genes 0.000 claims description 21
• 108010073385 Fibrin Proteins 0.000 claims description 21
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
• 229950003499 fibrin Drugs 0.000 claims description 21
• 150000002431 hydrogen Chemical class 0.000 claims description 20
• 229910052757 nitrogen Inorganic materials 0.000 claims description 19
• 229920006395 saturated elastomer Polymers 0.000 claims description 19
• 201000010099 disease Diseases 0.000 claims description 18
• 238000001356 surgical procedure Methods 0.000 claims description 17
• 230000002785 anti-thrombosis Effects 0.000 claims description 16
• 125000001188 haloalkyl group Chemical group 0.000 claims description 16
• 230000002265 prevention Effects 0.000 claims description 16
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 15
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 15
• 239000003146 anticoagulant agent Substances 0.000 claims description 15
• 230000015271 coagulation Effects 0.000 claims description 15
• 238000005345 coagulation Methods 0.000 claims description 15
• 229960000187 tissue plasminogen activator Drugs 0.000 claims description 15
• 108090000201 Carboxypeptidase B2 Proteins 0.000 claims description 14
• 208000006011 Stroke Diseases 0.000 claims description 14
• 125000000623 heterocyclic group Chemical group 0.000 claims description 13
• 229910052717 sulfur Inorganic materials 0.000 claims description 12
• 125000005842 heteroatom Chemical group 0.000 claims description 11
• 230000002685 pulmonary effect Effects 0.000 claims description 11
• 208000011580 syndromic disease Diseases 0.000 claims description 11
• 125000005843 halogen group Chemical group 0.000 claims description 10
• 208000010125 myocardial infarction Diseases 0.000 claims description 10
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 9
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 9
• 102100035023 Carboxypeptidase B2 Human genes 0.000 claims description 9
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 9
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 9
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 9
• 239000003085 diluting agent Substances 0.000 claims description 9
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
• 206010002383 Angina Pectoris Diseases 0.000 claims description 8
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
• 206010051055 Deep vein thrombosis Diseases 0.000 claims description 8
• 206010047249 Venous thrombosis Diseases 0.000 claims description 8
• 230000001965 increasing effect Effects 0.000 claims description 8
• 231100000241 scar Toxicity 0.000 claims description 8
• 208000032544 Cicatrix Diseases 0.000 claims description 7
• 208000018262 Peripheral vascular disease Diseases 0.000 claims description 7
• 238000000576 coating method Methods 0.000 claims description 7
• 238000012423 maintenance Methods 0.000 claims description 7
• 230000037387 scars Effects 0.000 claims description 7
• 230000001732 thrombotic effect Effects 0.000 claims description 7
• 208000005189 Embolism Diseases 0.000 claims description 6
• 230000001154 acute effect Effects 0.000 claims description 6
• 206010003119 arrhythmia Diseases 0.000 claims description 6
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
• 230000007211 cardiovascular event Effects 0.000 claims description 6
• 239000011248 coating agent Substances 0.000 claims description 6
• 230000000019 pro-fibrinolytic effect Effects 0.000 claims description 6
• 206010008132 Cerebral thrombosis Diseases 0.000 claims description 5
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
• 206010020772 Hypertension Diseases 0.000 claims description 5
• 201000001429 Intracranial Thrombosis Diseases 0.000 claims description 5
• 208000019693 Lung disease Diseases 0.000 claims description 5
• 201000004681 Psoriasis Diseases 0.000 claims description 5
• 125000003342 alkenyl group Chemical group 0.000 claims description 5
• 206010003246 arthritis Diseases 0.000 claims description 5
• 208000006673 asthma Diseases 0.000 claims description 5
• 238000005984 hydrogenation reaction Methods 0.000 claims description 5
• 201000010849 intracranial embolism Diseases 0.000 claims description 5
• 206010008088 Cerebral artery embolism Diseases 0.000 claims description 4
• 201000009273 Endometriosis Diseases 0.000 claims description 4
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
• 206010053159 Organ failure Diseases 0.000 claims description 4
• 206010040047 Sepsis Diseases 0.000 claims description 4
• 229960004676 antithrombotic agent Drugs 0.000 claims description 4
• 230000004770 neurodegeneration Effects 0.000 claims description 4
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
• 238000007892 surgical revascularization Methods 0.000 claims description 4
• 206010019280 Heart failures Diseases 0.000 claims description 3
• 208000010378 Pulmonary Embolism Diseases 0.000 claims description 3
• 238000009876 asymmetric hydrogenation reaction Methods 0.000 claims description 3
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
• 208000008487 fibromuscular dysplasia Diseases 0.000 claims description 3
• 230000003301 hydrolyzing effect Effects 0.000 claims description 3
• 125000002883 imidazolyl group Chemical group 0.000 claims description 3
• 229910052760 oxygen Inorganic materials 0.000 claims description 3
• 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
• 238000011477 surgical intervention Methods 0.000 claims description 3
• 125000000304 alkynyl group Chemical group 0.000 claims description 2
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• 206010012438 Dermatitis atopic Diseases 0.000 claims 2
• 208000001647 Renal Insufficiency Diseases 0.000 claims 2
• 201000008937 atopic dermatitis Diseases 0.000 claims 2
• 206010008118 cerebral infarction Diseases 0.000 claims 2
• 208000026106 cerebrovascular disease Diseases 0.000 claims 2
• 230000002757 inflammatory effect Effects 0.000 claims 2
• 201000006370 kidney failure Diseases 0.000 claims 2
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
• 206010039580 Scar Diseases 0.000 claims 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
• 230000000626 neurodegenerative effect Effects 0.000 claims 1
• 208000019553 vascular disease Diseases 0.000 claims 1
• 230000008901 benefit Effects 0.000 abstract description 3
• 230000002708 enhancing effect Effects 0.000 abstract description 2
• 230000002500 effect on skin Effects 0.000 abstract 1
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 266
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 227
• 239000000243 solution Substances 0.000 description 206
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 185
• 230000002829 reductive effect Effects 0.000 description 109
• 238000005160 1H NMR spectroscopy Methods 0.000 description 104
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 98
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 86
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 85
• 235000019439 ethyl acetate Nutrition 0.000 description 76
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 72
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 70
• 239000011541 reaction mixture Substances 0.000 description 68
• 238000006243 chemical reaction Methods 0.000 description 49
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
• 239000002904 solvent Substances 0.000 description 44
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 43
• 239000008367 deionised water Substances 0.000 description 42
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 42
• 229910021529 ammonia Inorganic materials 0.000 description 41
• 229910021641 deionized water Inorganic materials 0.000 description 41
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 40
• 239000000284 extract Substances 0.000 description 36
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
• 239000007787 solid Substances 0.000 description 34
• 238000010898 silica gel chromatography Methods 0.000 description 31
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 26
• 230000008569 process Effects 0.000 description 26
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 25
• 229920001467 poly(styrenesulfonates) Polymers 0.000 description 25
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 25
• 239000000047 product Substances 0.000 description 25
• 238000004255 ion exchange chromatography Methods 0.000 description 23
• 238000003556 assay Methods 0.000 description 22
• 238000004440 column chromatography Methods 0.000 description 22
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
• 238000001704 evaporation Methods 0.000 description 21
• 230000008020 evaporation Effects 0.000 description 21
• 238000010992 reflux Methods 0.000 description 21
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
• 230000015572 biosynthetic process Effects 0.000 description 20
• 239000011734 sodium Substances 0.000 description 20
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 19
• 239000003921 oil Substances 0.000 description 18
• 235000019198 oils Nutrition 0.000 description 18
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 18
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
• 150000001412 amines Chemical class 0.000 description 15
• 239000008346 aqueous phase Substances 0.000 description 15
• 239000000706 filtrate Substances 0.000 description 15
• 239000010410 layer Substances 0.000 description 15
• 108090000765 processed proteins & peptides Proteins 0.000 description 15
• 239000012043 crude product Substances 0.000 description 14
• 230000020764 fibrinolysis Effects 0.000 description 14
• 238000004809 thin layer chromatography Methods 0.000 description 14
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
• 239000000741 silica gel Substances 0.000 description 13
• 229910002027 silica gel Inorganic materials 0.000 description 13
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
• 239000002253 acid Substances 0.000 description 12
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 12
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
• 229910000104 sodium hydride Inorganic materials 0.000 description 12
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 12
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
• 150000001299 aldehydes Chemical class 0.000 description 11
• 235000019270 ammonium chloride Nutrition 0.000 description 11
• 239000007864 aqueous solution Substances 0.000 description 11
• 239000003480 eluent Substances 0.000 description 11
• 239000006260 foam Substances 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 239000000725 suspension Substances 0.000 description 11
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
• 108010085169 Lysine carboxypeptidase Proteins 0.000 description 10
• 238000005481 NMR spectroscopy Methods 0.000 description 10
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
• 150000001336 alkenes Chemical class 0.000 description 10
• 239000012230 colorless oil Substances 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 239000002480 mineral oil Substances 0.000 description 10
• 235000010446 mineral oil Nutrition 0.000 description 10
• 239000012074 organic phase Substances 0.000 description 10
• 239000012312 sodium hydride Substances 0.000 description 10
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 230000000740 bleeding effect Effects 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 229910052799 carbon Inorganic materials 0.000 description 9
• 239000007858 starting material Substances 0.000 description 9
• 102400000967 Bradykinin Human genes 0.000 description 8
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
• 230000017531 blood circulation Effects 0.000 description 8
• 239000006185 dispersion Substances 0.000 description 8
• 230000000694 effects Effects 0.000 description 8
• 238000010828 elution Methods 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 239000002808 molecular sieve Substances 0.000 description 8
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 8
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 8
• OTDGPKRCQXSTPV-JTQLQIEISA-N (2s)-5-azaniumyl-2-[(1-propylimidazol-4-yl)methyl]pentanoate Chemical compound CCCN1C=NC(C[C@H](CCCN)C(O)=O)=C1 OTDGPKRCQXSTPV-JTQLQIEISA-N 0.000 description 7
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 7
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
• 238000005804 alkylation reaction Methods 0.000 description 7
• 239000012267 brine Substances 0.000 description 7
• 208000014674 injury Diseases 0.000 description 7
• 239000003456 ion exchange resin Substances 0.000 description 7
• 229920003303 ion-exchange polymer Polymers 0.000 description 7
• 230000014759 maintenance of location Effects 0.000 description 7
• 239000012299 nitrogen atmosphere Substances 0.000 description 7
• 125000006239 protecting group Chemical group 0.000 description 7
• LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 7
• 239000011347 resin Substances 0.000 description 7
• 229920005989 resin Polymers 0.000 description 7
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• UVTMXVBQOPVNHA-JTQLQIEISA-N (2s)-2-(2-aminoethylamino)-3-(1-propylimidazol-4-yl)propanoic acid Chemical compound CCCN1C=NC(C[C@H](NCCN)C(O)=O)=C1 UVTMXVBQOPVNHA-JTQLQIEISA-N 0.000 description 6
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
• 102000003847 Carboxypeptidase B2 Human genes 0.000 description 6
• 229920000858 Cyclodextrin Polymers 0.000 description 6
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
• 108090000190 Thrombin Proteins 0.000 description 6
• 229960001138 acetylsalicylic acid Drugs 0.000 description 6
• 150000001413 amino acids Chemical class 0.000 description 6
• 229920001429 chelating resin Polymers 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 238000004587 chromatography analysis Methods 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 208000029078 coronary artery disease Diseases 0.000 description 6
• 238000000354 decomposition reaction Methods 0.000 description 6
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 6
• 150000003951 lactams Chemical class 0.000 description 6
• DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 6
• 239000001632 sodium acetate Substances 0.000 description 6
• 235000017281 sodium acetate Nutrition 0.000 description 6
• 229910000029 sodium carbonate Inorganic materials 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 5
• 241000282472 Canis lupus familiaris Species 0.000 description 5
• 229910021591 Copper(I) chloride Inorganic materials 0.000 description 5
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
• ULMHMJAEGZPQRY-UHFFFAOYSA-N N-(tert-butoxycarbonyl)piperidin-2-one Chemical compound CC(C)(C)OC(=O)N1CCCCC1=O ULMHMJAEGZPQRY-UHFFFAOYSA-N 0.000 description 5
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
• 102000013566 Plasminogen Human genes 0.000 description 5
• 108010051456 Plasminogen Proteins 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 229940024606 amino acid Drugs 0.000 description 5
• 235000001014 amino acid Nutrition 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 5
• 238000010511 deprotection reaction Methods 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 238000004090 dissolution Methods 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 238000006460 hydrolysis reaction Methods 0.000 description 5
• 238000001802 infusion Methods 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 239000012071 phase Substances 0.000 description 5
• 235000019260 propionic acid Nutrition 0.000 description 5
• 235000017557 sodium bicarbonate Nutrition 0.000 description 5
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
• 238000003756 stirring Methods 0.000 description 5
• 229960004072 thrombin Drugs 0.000 description 5
• 230000008733 trauma Effects 0.000 description 5
• XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 4
• YHBCRXAIIVZWEW-UHFFFAOYSA-N 2-[3-(diaminomethylideneamino)phenyl]-3-sulfanylpropanoic acid Chemical compound NC(=N)NC1=CC=CC(C(CS)C(O)=O)=C1 YHBCRXAIIVZWEW-UHFFFAOYSA-N 0.000 description 4
• OTDGPKRCQXSTPV-UHFFFAOYSA-N 5-azaniumyl-2-[(1-propylimidazol-4-yl)methyl]pentanoate Chemical compound CCCN1C=NC(CC(CCCN)C(O)=O)=C1 OTDGPKRCQXSTPV-UHFFFAOYSA-N 0.000 description 4
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
• 102000005367 Carboxypeptidases Human genes 0.000 description 4
• 108010006303 Carboxypeptidases Proteins 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 229960000583 acetic acid Drugs 0.000 description 4
• 235000011114 ammonium hydroxide Nutrition 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 239000003054 catalyst Substances 0.000 description 4
• 230000035602 clotting Effects 0.000 description 4
• FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
• 230000003287 optical effect Effects 0.000 description 4
• 229910052763 palladium Inorganic materials 0.000 description 4
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
• 230000010410 reperfusion Effects 0.000 description 4
• 150000003384 small molecules Chemical class 0.000 description 4
• 229910000033 sodium borohydride Inorganic materials 0.000 description 4
• 239000012279 sodium borohydride Substances 0.000 description 4
• 239000008107 starch Substances 0.000 description 4
• 229940032147 starch Drugs 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• ACNRTYKOPZDRCO-UHFFFAOYSA-N tert-butyl n-(2-oxoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC=O ACNRTYKOPZDRCO-UHFFFAOYSA-N 0.000 description 4
• 238000002054 transplantation Methods 0.000 description 4
• 230000002792 vascular Effects 0.000 description 4
• 230000003966 vascular damage Effects 0.000 description 4
• XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 3
• ZQEXIXXJFSQPNA-UHFFFAOYSA-N 1h-imidazole-5-carbaldehyde Chemical compound O=CC1=CNC=N1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• APISFIHOBKRZOG-UHFFFAOYSA-N 6-amino-2-[(1-propylimidazol-4-yl)methyl]hexanoic acid Chemical compound CCCN1C=NC(CC(CCCCN)C(O)=O)=C1 APISFIHOBKRZOG-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
• 201000004624 Dermatitis Diseases 0.000 description 3
• 102000010911 Enzyme Precursors Human genes 0.000 description 3
• 108010062466 Enzyme Precursors Proteins 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 206010022489 Insulin Resistance Diseases 0.000 description 3
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
• 208000002193 Pain Diseases 0.000 description 3
• 208000018737 Parkinson disease Diseases 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 239000002168 alkylating agent Substances 0.000 description 3
• 229940100198 alkylating agent Drugs 0.000 description 3
• 230000029936 alkylation Effects 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
• OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 238000000502 dialysis Methods 0.000 description 3
• 230000003028 elevating effect Effects 0.000 description 3
• PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 150000004820 halides Chemical class 0.000 description 3
• 210000002216 heart Anatomy 0.000 description 3
• 230000002439 hemostatic effect Effects 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 3
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 238000005342 ion exchange Methods 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
• RWEVEEORUORBAX-VIFPVBQESA-N methyl (2s)-3-(1h-imidazol-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OC)CC1=CNC=N1 RWEVEEORUORBAX-VIFPVBQESA-N 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 230000036407 pain Effects 0.000 description 3
• 235000019271 petrolatum Nutrition 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• 229960001404 quinidine Drugs 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000006722 reduction reaction Methods 0.000 description 3
• 208000037803 restenosis Diseases 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
• WGCSLWNGKNXCMO-CYBMUJFWSA-N tert-butyl (3r)-2-oxo-3-[(1-propylimidazol-4-yl)methyl]piperidine-1-carboxylate Chemical compound CCCN1C=NC(C[C@@H]2C(N(C(=O)OC(C)(C)C)CCC2)=O)=C1 WGCSLWNGKNXCMO-CYBMUJFWSA-N 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
• HRGIXOAUBWGTCB-SSDOTTSWSA-N (2r)-2-(2-aminoethylamino)-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NCCN[C@@H](C(O)=O)CC1=CNC=N1 HRGIXOAUBWGTCB-SSDOTTSWSA-N 0.000 description 2
• JZLQYMHAXPPICX-RXMQYKEDSA-N (2r)-2-chloro-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@H](Cl)CC1=CNC=N1 JZLQYMHAXPPICX-RXMQYKEDSA-N 0.000 description 2
• KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 2
• LLJMTPSWZYCMHR-NSHDSACASA-N (2s)-2-(2-aminoethylamino)-3-(1-butylimidazol-4-yl)propanoic acid Chemical compound CCCCN1C=NC(C[C@H](NCCN)C(O)=O)=C1 LLJMTPSWZYCMHR-NSHDSACASA-N 0.000 description 2
• NPKZUKQZSWBBHG-NSHDSACASA-N (2s)-2-(2-aminoethylamino)-3-[1-(1,3-thiazol-5-ylmethyl)imidazol-4-yl]propanoic acid Chemical compound C1=NC(C[C@H](NCCN)C(O)=O)=CN1CC1=CN=CS1 NPKZUKQZSWBBHG-NSHDSACASA-N 0.000 description 2
• YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
• ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 2
• BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
• VKVCLXDFOQQABP-UHFFFAOYSA-N 2-[2-(diaminomethylideneamino)ethylsulfanyl]butanedioic acid Chemical compound NC(N)=NCCSC(C(O)=O)CC(O)=O VKVCLXDFOQQABP-UHFFFAOYSA-N 0.000 description 2
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 101000946522 Bos taurus Carboxypeptidase B Proteins 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 108090000087 Carboxypeptidase B Proteins 0.000 description 2
• 102000003670 Carboxypeptidase B Human genes 0.000 description 2
• 206010053567 Coagulopathies Diseases 0.000 description 2
• 206010058314 Dysplasia Diseases 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 108010049003 Fibrinogen Proteins 0.000 description 2
• 102000008946 Fibrinogen Human genes 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• BXRMEWOQUXOLDH-LURJTMIESA-N L-Histidine methyl ester Chemical compound COC(=O)[C@@H](N)CC1=CN=CN1 BXRMEWOQUXOLDH-LURJTMIESA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 235000019502 Orange oil Nutrition 0.000 description 2
• 239000004264 Petrolatum Substances 0.000 description 2
• 244000061456 Solanum tuberosum Species 0.000 description 2
• 235000002595 Solanum tuberosum Nutrition 0.000 description 2
• 102100026966 Thrombomodulin Human genes 0.000 description 2
• 108010079274 Thrombomodulin Proteins 0.000 description 2
• 208000031737 Tissue Adhesions Diseases 0.000 description 2
• 208000024248 Vascular System injury Diseases 0.000 description 2
• 208000012339 Vascular injury Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
• 230000001567 anti-fibrinolytic effect Effects 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 238000006254 arylation reaction Methods 0.000 description 2
• 230000023555 blood coagulation Effects 0.000 description 2
• 230000036770 blood supply Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 238000007887 coronary angioplasty Methods 0.000 description 2
• 210000004351 coronary vessel Anatomy 0.000 description 2
• ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 238000000132 electrospray ionisation Methods 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 229940012952 fibrinogen Drugs 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 230000013632 homeostatic process Effects 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 229940030980 inova Drugs 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 239000010502 orange oil Substances 0.000 description 2
• 239000012044 organic layer Substances 0.000 description 2
• 229940066842 petrolatum Drugs 0.000 description 2
• 229940012957 plasmin Drugs 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 239000003805 procoagulant Substances 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
• XJVZHKXGDQXSNT-UHFFFAOYSA-N tert-butyl n-[2-[methoxy(methyl)amino]-2-oxoethyl]carbamate Chemical compound CON(C)C(=O)CNC(=O)OC(C)(C)C XJVZHKXGDQXSNT-UHFFFAOYSA-N 0.000 description 2
• HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• ITHXTSANOXLYDY-RXMQYKEDSA-N (2r)-2-[(2-bromoacetyl)amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@H](C(O)=O)NC(=O)CBr ITHXTSANOXLYDY-RXMQYKEDSA-N 0.000 description 1
• FCFWEOGTZZPCTO-MRVPVSSYSA-N (2r)-3,6-dimethoxy-2-propan-2-yl-2,5-dihydropyrazine Chemical compound COC1=N[C@H](C(C)C)C(OC)=NC1 FCFWEOGTZZPCTO-MRVPVSSYSA-N 0.000 description 1
• BJQWDKXNACRDDN-SSDOTTSWSA-N (2r)-5-amino-2-(1h-imidazol-5-ylmethyl)pentanoic acid Chemical compound NCCC[C@@H](C(O)=O)CC1=CNC=N1 BJQWDKXNACRDDN-SSDOTTSWSA-N 0.000 description 1
• IXFBXFWVMCKOHZ-LLVKDONJSA-N (2r)-5-amino-2-[(1-butylimidazol-4-yl)methyl]pentanoic acid Chemical compound CCCCN1C=NC(C[C@@H](CCCN)C(O)=O)=C1 IXFBXFWVMCKOHZ-LLVKDONJSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• CKGDTHHWMZCQDH-JTQLQIEISA-N (2s)-2-(1,4-diazepan-1-yl)-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)N1CCNCCC1)C1=CNC=N1 CKGDTHHWMZCQDH-JTQLQIEISA-N 0.000 description 1
• RVUXHJZTETWWDB-VIFPVBQESA-N (2s)-2-(2-aminoethylamino)-3-(1-ethylimidazol-4-yl)propanoic acid Chemical compound CCN1C=NC(C[C@H](NCCN)C(O)=O)=C1 RVUXHJZTETWWDB-VIFPVBQESA-N 0.000 description 1
• ZIGWTNNVVANKME-QMMMGPOBSA-N (2s)-2-(2-aminoethylamino)-3-(1-methylimidazol-4-yl)propanoic acid Chemical compound CN1C=NC(C[C@H](NCCN)C(O)=O)=C1 ZIGWTNNVVANKME-QMMMGPOBSA-N 0.000 description 1
• XZDAXLNUXHTEAZ-LURJTMIESA-N (2s)-2-(2-aminoethylamino)-3-(1h-imidazol-2-yl)propanoic acid Chemical compound NCCN[C@H](C(O)=O)CC1=NC=CN1 XZDAXLNUXHTEAZ-LURJTMIESA-N 0.000 description 1
• HRGIXOAUBWGTCB-ZETCQYMHSA-N (2s)-2-(2-aminoethylamino)-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NCCN[C@H](C(O)=O)CC1=CNC=N1 HRGIXOAUBWGTCB-ZETCQYMHSA-N 0.000 description 1
• UPOWVJPHTYASQZ-QMMMGPOBSA-N (2s)-2-(2-aminoethylamino)-3-[1-(carboxymethyl)imidazol-4-yl]propanoic acid Chemical compound NCCN[C@H](C(O)=O)CC1=CN(CC(O)=O)C=N1 UPOWVJPHTYASQZ-QMMMGPOBSA-N 0.000 description 1
• GBDMZXRVSWVUNJ-RGURZIINSA-N (2s)-2-[(1-amino-3-methylbutan-2-yl)amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound CC(C)C(CN)N[C@H](C(O)=O)CC1=CNC=N1 GBDMZXRVSWVUNJ-RGURZIINSA-N 0.000 description 1
• IYRZGGUIWNGYNV-PYMCNQPYSA-N (2s)-2-[(1-amino-3-phenylpropan-2-yl)amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound N([C@@H](CC=1N=CNC=1)C(O)=O)C(CN)CC1=CC=CC=C1 IYRZGGUIWNGYNV-PYMCNQPYSA-N 0.000 description 1
• HSDUKFOOYACLBO-QMMMGPOBSA-N (2s)-2-[2-aminoethyl(methyl)amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NCCN(C)[C@H](C(O)=O)CC1=CNC=N1 HSDUKFOOYACLBO-QMMMGPOBSA-N 0.000 description 1
• KCMTVJQUIHHGHR-OOZYFLPDSA-N (2s)-2-[[(2r,3s)-3-aminobutan-2-yl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C[C@H](N)[C@@H](C)N[C@H](C(O)=O)CC1=CNC=N1 KCMTVJQUIHHGHR-OOZYFLPDSA-N 0.000 description 1
• RSBLYDDDDLUCLE-ZDUSSCGKSA-N (2s)-5-[(2-methylpropan-2-yl)oxycarbonylamino]-2-[(1-propylimidazol-4-yl)methyl]pentanoic acid Chemical compound CCCN1C=NC(C[C@H](CCCNC(=O)OC(C)(C)C)C(O)=O)=C1 RSBLYDDDDLUCLE-ZDUSSCGKSA-N 0.000 description 1
• BJQWDKXNACRDDN-ZETCQYMHSA-N (2s)-5-amino-2-(1h-imidazol-5-ylmethyl)pentanoic acid Chemical compound NCCC[C@H](C(O)=O)CC1=CNC=N1 BJQWDKXNACRDDN-ZETCQYMHSA-N 0.000 description 1
• 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
• LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
• KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
• ZPIHRUCXNRKJIF-UHFFFAOYSA-N 1-(2-trimethylsilylethoxymethyl)imidazole-2-carbaldehyde Chemical compound C[Si](C)(C)CCOCN1C=CN=C1C=O ZPIHRUCXNRKJIF-UHFFFAOYSA-N 0.000 description 1
• DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
• OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
• DHGMDHQNUNRMIN-UHFFFAOYSA-N 1-benzylpyrrolidin-3-one Chemical compound C1C(=O)CCN1CC1=CC=CC=C1 DHGMDHQNUNRMIN-UHFFFAOYSA-N 0.000 description 1
• YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 1
• NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 1
• MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
• CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
• PESXKUUFXACUMT-UHFFFAOYSA-N 1-butylimidazole-4-carbaldehyde Chemical compound CCCCN1C=NC(C=O)=C1 PESXKUUFXACUMT-UHFFFAOYSA-N 0.000 description 1
• GGYVTHJIUNGKFZ-UHFFFAOYSA-N 1-methylpiperidin-2-one Chemical compound CN1CCCCC1=O GGYVTHJIUNGKFZ-UHFFFAOYSA-N 0.000 description 1
• 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• CLMVJORCTWUXKP-UHFFFAOYSA-N 1h-imidazol-2-yl propanoate Chemical compound CCC(=O)OC1=NC=CN1 CLMVJORCTWUXKP-UHFFFAOYSA-N 0.000 description 1
• SAXTXIDZMKZQMV-UHFFFAOYSA-N 2-(2-bromoethyl)pyridin-1-ium;bromide Chemical compound Br.BrCCC1=CC=CC=N1 SAXTXIDZMKZQMV-UHFFFAOYSA-N 0.000 description 1
• ISKXXOHISPGNSB-NVXWUHKLSA-N 2-[[2-[[(2r,5r)-3,6-dimethoxy-5-propan-2-yl-2,5-dihydropyrazin-2-yl]methyl]imidazol-1-yl]methoxy]ethyl-trimethylsilane Chemical compound COC1=N[C@H](C(C)C)C(OC)=N[C@@H]1CC1=NC=CN1COCC[Si](C)(C)C ISKXXOHISPGNSB-NVXWUHKLSA-N 0.000 description 1
• PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
• SRDNJJJAHZNVBC-UHFFFAOYSA-N 2-bromo-n-[4-(diaminomethylideneamino)butyl]acetamide Chemical compound NC(=N)NCCCCNC(=O)CBr SRDNJJJAHZNVBC-UHFFFAOYSA-N 0.000 description 1
• LBVZINOLAFTARU-UHFFFAOYSA-N 2-bromo-n-methylacetamide Chemical compound CNC(=O)CBr LBVZINOLAFTARU-UHFFFAOYSA-N 0.000 description 1
• DOGFOANXOUKFEC-UHFFFAOYSA-N 2-bromopentanal Chemical compound CCCC(Br)C=O DOGFOANXOUKFEC-UHFFFAOYSA-N 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
• PQMQIYHBJLVVTD-UHFFFAOYSA-N 2-oxopiperidin-1-ium-1-carboxylate Chemical compound OC(=O)N1CCCCC1=O PQMQIYHBJLVVTD-UHFFFAOYSA-N 0.000 description 1
• DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
• 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
• CFJFHWBHHNZXHO-UHFFFAOYSA-N 4-propyl-1-(2-trimethylsilylethoxymethyl)imidazole-2-carbaldehyde Chemical compound CCCC1=CN(COCC[Si](C)(C)C)C(C=O)=N1 CFJFHWBHHNZXHO-UHFFFAOYSA-N 0.000 description 1
• YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
• ZIESYFUVRJDNNW-UHFFFAOYSA-N 5-(chloromethyl)-1,3-thiazole;hydrochloride Chemical compound Cl.ClCC1=CN=CS1 ZIESYFUVRJDNNW-UHFFFAOYSA-N 0.000 description 1
• PIOYVIQXEZHHET-UHFFFAOYSA-N 5-(methylamino)-2-[[1-(3-methylbutyl)imidazol-4-yl]methyl]pentanoic acid Chemical compound CNCCCC(C(O)=O)CC1=CN(CCC(C)C)C=N1 PIOYVIQXEZHHET-UHFFFAOYSA-N 0.000 description 1
• BJQWDKXNACRDDN-UHFFFAOYSA-N 5-amino-2-(1h-imidazol-5-ylmethyl)pentanoic acid Chemical compound NCCCC(C(O)=O)CC1=CNC=N1 BJQWDKXNACRDDN-UHFFFAOYSA-N 0.000 description 1
• BSUKBOUHTXROIW-UHFFFAOYSA-N 5-amino-2-[(1-phenylimidazol-4-yl)methyl]pentanoic acid Chemical compound C1=NC(CC(CCCN)C(O)=O)=CN1C1=CC=CC=C1 BSUKBOUHTXROIW-UHFFFAOYSA-N 0.000 description 1
• WXWYBESKOJOXPF-UHFFFAOYSA-N 5-amino-2-[[1-(3-methylbutyl)imidazol-4-yl]methyl]pentanoic acid Chemical compound CC(C)CCN1C=NC(CC(CCCN)C(O)=O)=C1 WXWYBESKOJOXPF-UHFFFAOYSA-N 0.000 description 1
• ZMXHZXBHERWGMW-UHFFFAOYSA-N 5-propyl-1-(2-trimethylsilylethoxymethyl)imidazole-2-carbaldehyde Chemical compound CCCC1=CN=C(C=O)N1COCC[Si](C)(C)C ZMXHZXBHERWGMW-UHFFFAOYSA-N 0.000 description 1
• XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 201000005657 Antithrombin III deficiency Diseases 0.000 description 1
• 200000000007 Arterial disease Diseases 0.000 description 1
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
• 208000025978 Athletic injury Diseases 0.000 description 1
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
• 206010004053 Bacterial toxaemia Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• WTWHKYAHEHUQNG-UHFFFAOYSA-N CC1=CC(=C(C=C1)S(=O)(=O)O)C(C)COC Chemical compound CC1=CC(=C(C=C1)S(=O)(=O)O)C(C)COC WTWHKYAHEHUQNG-UHFFFAOYSA-N 0.000 description 1
• BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
• 101150041968 CDC13 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• 229940121981 Carboxypeptidase inhibitor Drugs 0.000 description 1
• 101710127041 Carboxypeptidase inhibitor Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 241000270281 Coluber constrictor Species 0.000 description 1
• 208000034656 Contusions Diseases 0.000 description 1
• 241000766026 Coregonus nasus Species 0.000 description 1
• 241001354243 Corona Species 0.000 description 1
• 241000711573 Coronaviridae Species 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
• 208000032928 Dyslipidaemia Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 108010056764 Eptifibatide Proteins 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
• 108010014172 Factor V Proteins 0.000 description 1
• 229940122564 Factor X inhibitor Drugs 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• SPJOZZSIXXJYBT-UHFFFAOYSA-N Fenson Chemical compound C1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 SPJOZZSIXXJYBT-UHFFFAOYSA-N 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 102000007625 Hirudins Human genes 0.000 description 1
• 108010007267 Hirudins Proteins 0.000 description 1
• 101100438614 Homo sapiens CPB1 gene Proteins 0.000 description 1
• 101000946518 Homo sapiens Carboxypeptidase B2 Proteins 0.000 description 1
• 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 208000017170 Lipid metabolism disease Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 101710140999 Metallocarboxypeptidase inhibitor Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
• 208000008826 Obstetric Labor Complications Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• 208000008601 Polycythemia Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000012287 Prolapse Diseases 0.000 description 1
• WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 101800004937 Protein C Proteins 0.000 description 1
• 102000017975 Protein C Human genes 0.000 description 1
• 201000005660 Protein C Deficiency Diseases 0.000 description 1
• 206010051292 Protein S Deficiency Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 206010038563 Reocclusion Diseases 0.000 description 1
• 101800001700 Saposin-D Proteins 0.000 description 1
• 229910004298 SiO 2 Inorganic materials 0.000 description 1
• 206010040860 Skin haemorrhages Diseases 0.000 description 1
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
• 208000007718 Stable Angina Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 108010023197 Streptokinase Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
• 229940122388 Thrombin inhibitor Drugs 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 102000002262 Thromboplastin Human genes 0.000 description 1
• 208000013222 Toxemia Diseases 0.000 description 1
• 208000003441 Transfusion reaction Diseases 0.000 description 1
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• DWAYENIPKPKKMV-ILKKLZGPSA-N [(2s)-3-(1h-imidazol-3-ium-4-yl)-1-methoxy-1-oxopropan-2-yl]azanium;dichloride Chemical compound Cl.Cl.COC(=O)[C@@H](N)CC1=CN=CN1 DWAYENIPKPKKMV-ILKKLZGPSA-N 0.000 description 1
• GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical group [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 229940000279 aggrastat Drugs 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960005260 amiodarone Drugs 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
• 239000003416 antiarrhythmic agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• 239000011260 aqueous acid Substances 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 238000005810 carbonylation reaction Methods 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229940081733 cetearyl alcohol Drugs 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000012069 chiral reagent Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 230000008576 chronic process Effects 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 239000003245 coal Substances 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000002485 combustion reaction Methods 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000011443 conventional therapy Methods 0.000 description 1
• RFKZUAOAYVHBOY-UHFFFAOYSA-M copper(1+);acetate Chemical compound [Cu+].CC([O-])=O RFKZUAOAYVHBOY-UHFFFAOYSA-M 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 208000026758 coronary atherosclerosis Diseases 0.000 description 1
• 229960000956 coumarin Drugs 0.000 description 1
• 235000001671 coumarin Nutrition 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 229940045803 cuprous chloride Drugs 0.000 description 1
• 238000009109 curative therapy Methods 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
• 229960005156 digoxin Drugs 0.000 description 1
• LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
• 229960002768 dipyridamole Drugs 0.000 description 1
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
• OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 229940112141 dry powder inhaler Drugs 0.000 description 1
• 238000010410 dusting Methods 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000008387 emulsifying waxe Substances 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• 239000002024 ethyl acetate extract Substances 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 229940049370 fibrinolysis inhibitor Drugs 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• OQZCSNDVOWYALR-UHFFFAOYSA-N flurochloridone Chemical compound FC(F)(F)C1=CC=CC(N2C(C(Cl)C(CCl)C2)=O)=C1 OQZCSNDVOWYALR-UHFFFAOYSA-N 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000005227 gel permeation chromatography Methods 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 229940049654 glyceryl behenate Drugs 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 238000005658 halogenation reaction Methods 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 239000002874 hemostatic agent Substances 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
• 238000004896 high resolution mass spectrometry Methods 0.000 description 1
• 229940006607 hirudin Drugs 0.000 description 1
• WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229960002885 histidine Drugs 0.000 description 1
• 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
• 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229940056984 integrilin Drugs 0.000 description 1
• 208000003243 intestinal obstruction Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 150000002605 large molecules Chemical class 0.000 description 1
• JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 1
• OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
• 229960004408 lepirudin Drugs 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 229940002661 lipitor Drugs 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
• FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 201000005857 malignant hypertension Diseases 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 239000000155 melt Substances 0.000 description 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
• 229910052753 mercury Inorganic materials 0.000 description 1
• 229910052987 metal hydride Inorganic materials 0.000 description 1
• 150000004681 metal hydrides Chemical class 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 230000006510 metastatic growth Effects 0.000 description 1
• 239000000401 methanolic extract Substances 0.000 description 1
• BXRMEWOQUXOLDH-ZCFIWIBFSA-N methyl (2r)-2-amino-3-(1h-imidazol-5-yl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CN=CN1 BXRMEWOQUXOLDH-ZCFIWIBFSA-N 0.000 description 1
• UTSKMJBFWZOTOD-KLXURFKVSA-N methyl (2s)-2-amino-3-(1-methylimidazol-4-yl)propanoate;dihydrochloride Chemical compound Cl.Cl.COC(=O)[C@@H](N)CC1=CN(C)C=N1 UTSKMJBFWZOTOD-KLXURFKVSA-N 0.000 description 1
• SPYVYWCBBVEEBH-DEOSSOPVSA-N methyl (2s)-2-amino-3-(1-tritylimidazol-4-yl)propanoate Chemical compound C1=NC(C[C@H](N)C(=O)OC)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 SPYVYWCBBVEEBH-DEOSSOPVSA-N 0.000 description 1
• GHGYFVAFDSNOPO-NSHDSACASA-N methyl (2s)-3-(1h-imidazol-5-yl)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylamino]propanoate Chemical compound CC(C)(C)OC(=O)NCCN[C@H](C(=O)OC)CC1=CNC=N1 GHGYFVAFDSNOPO-NSHDSACASA-N 0.000 description 1
• WCRFAUOLNAZNCA-MLWJPKLSSA-N methyl (2s)-3-imidazolidin-4-yl-2-(methylamino)propanoate Chemical compound COC(=O)[C@@H](NC)CC1CNCN1 WCRFAUOLNAZNCA-MLWJPKLSSA-N 0.000 description 1
• OQZHDZZHFRRIMH-XFXZXTDPSA-N methyl (z)-3-(1h-imidazol-2-yl)-2-(phenylmethoxycarbonylamino)prop-2-enoate Chemical compound N=1C=CNC=1/C=C(C(=O)OC)\NC(=O)OCC1=CC=CC=C1 OQZHDZZHFRRIMH-XFXZXTDPSA-N 0.000 description 1
• VLZKPLZUZGWKOT-UHFFFAOYSA-N methyl 3-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)propanoate Chemical compound COP(=O)(OC)CC(C(=O)OC)NC(=O)OCC1=CC=CC=C1 VLZKPLZUZGWKOT-UHFFFAOYSA-N 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• PTVBBIMKLOMGSY-UHFFFAOYSA-N n,n-bis(2-chloroethyl)-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N(CCCl)CCCl)C=C1 PTVBBIMKLOMGSY-UHFFFAOYSA-N 0.000 description 1
• BXVCFLARGCBLEP-UHFFFAOYSA-N n-(2-bromoethyl)methanesulfonamide Chemical compound CS(=O)(=O)NCCBr BXVCFLARGCBLEP-UHFFFAOYSA-N 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 208000009928 nephrosis Diseases 0.000 description 1
• 231100001027 nephrosis Toxicity 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000000399 orthopedic effect Effects 0.000 description 1
• AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 210000003254 palate Anatomy 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 125000005561 phenanthryl group Chemical group 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 230000010118 platelet activation Effects 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 229940020573 plavix Drugs 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 230000009862 primary prevention Effects 0.000 description 1
• FXSZGKYGUFCBQY-UHFFFAOYSA-N propanoic acid;dihydrochloride Chemical compound Cl.Cl.CCC(O)=O FXSZGKYGUFCBQY-UHFFFAOYSA-N 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 230000004224 protection Effects 0.000 description 1
• 229960000856 protein c Drugs 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000005932 reductive alkylation reaction Methods 0.000 description 1
• 229940107685 reopro Drugs 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000002151 riboflavin Substances 0.000 description 1
• 101150006605 rpa gene Proteins 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000009863 secondary prevention Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• 235000010288 sodium nitrite Nutrition 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000001587 sorbitan monostearate Substances 0.000 description 1
• 235000011076 sorbitan monostearate Nutrition 0.000 description 1
• 229940035048 sorbitan monostearate Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000012258 stirred mixture Substances 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 229960005202 streptokinase Drugs 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 239000013076 target substance Substances 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• PGYYPXUDDSFUFW-JLHYYAGUSA-N tert-butyl (3e)-2-oxo-3-[(1-propylimidazol-4-yl)methylidene]piperidine-1-carboxylate Chemical compound CCCN1C=NC(\C=C/2C(N(C(=O)OC(C)(C)C)CCC\2)=O)=C1 PGYYPXUDDSFUFW-JLHYYAGUSA-N 0.000 description 1
• WQIPIFTWSQKVPZ-UHFFFAOYSA-N tert-butyl 3-[[1-(3-methylbutyl)imidazol-4-yl]methyl]-2-oxopiperidine-1-carboxylate Chemical compound CC(C)CCN1C=NC(CC2C(N(C(=O)OC(C)(C)C)CCC2)=O)=C1 WQIPIFTWSQKVPZ-UHFFFAOYSA-N 0.000 description 1
• YMPBAJJEOMXWSZ-UHFFFAOYSA-N tert-butyl 3-[hydroxy-(1-propylimidazol-4-yl)methyl]-2-oxopiperidine-1-carboxylate Chemical compound CCCN1C=NC(C(O)C2C(N(C(=O)OC(C)(C)C)CCC2)=O)=C1 YMPBAJJEOMXWSZ-UHFFFAOYSA-N 0.000 description 1
• SRPFEPWIXYNJHV-UHFFFAOYSA-N tert-butyl 3-[hydroxy-(1-tritylimidazol-4-yl)methyl]-2-oxopiperidine-1-carboxylate Chemical compound O=C1N(C(=O)OC(C)(C)C)CCCC1C(O)C1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 SRPFEPWIXYNJHV-UHFFFAOYSA-N 0.000 description 1
• PWQIGBOSLQHOBT-ZETCQYMHSA-N tert-butyl n-[(2s)-1-[methoxy(methyl)amino]-1-oxopropan-2-yl]carbamate Chemical compound CON(C)C(=O)[C@H](C)NC(=O)OC(C)(C)C PWQIGBOSLQHOBT-ZETCQYMHSA-N 0.000 description 1
• NUAKKRMYBBXGFP-LURJTMIESA-N tert-butyl n-[(2s)-3-oxobutan-2-yl]carbamate Chemical compound CC(=O)[C@H](C)NC(=O)OC(C)(C)C NUAKKRMYBBXGFP-LURJTMIESA-N 0.000 description 1
• XODUGXDTYDHWBN-UHFFFAOYSA-N tert-butyl n-benzyl-n-(4-iodobutyl)carbamate Chemical compound ICCCCN(C(=O)OC(C)(C)C)CC1=CC=CC=C1 XODUGXDTYDHWBN-UHFFFAOYSA-N 0.000 description 1
• FWOBBEOKTITUHK-UHFFFAOYSA-N tert-butyl n-benzylcarbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC=C1 FWOBBEOKTITUHK-UHFFFAOYSA-N 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 229960003766 thrombin (human) Drugs 0.000 description 1
• 239000003868 thrombin inhibitor Substances 0.000 description 1
• 201000005665 thrombophilia Diseases 0.000 description 1
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
• 229960005001 ticlopidine Drugs 0.000 description 1
• COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
• 206010044008 tonsillitis Diseases 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000011426 transformation method Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
• XKAHOROBQULDNH-UHFFFAOYSA-N trimethyl-[2-[(4-propylimidazol-1-yl)methoxy]ethyl]silane Chemical compound CCCC1=CN(COCC[Si](C)(C)C)C=N1 XKAHOROBQULDNH-UHFFFAOYSA-N 0.000 description 1
• WVVKDAYKVPLQGF-UHFFFAOYSA-N trimethyl-[2-[(5-propylimidazol-1-yl)methoxy]ethyl]silane Chemical compound CCCC1=CN=CN1COCC[Si](C)(C)C WVVKDAYKVPLQGF-UHFFFAOYSA-N 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 229960005356 urokinase Drugs 0.000 description 1
• 238000005292 vacuum distillation Methods 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 239000003643 water by type Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1